Company intelligence / Profile preview

River BioMedics

Enschede, Netherlandsriverbiomedics.com ↗

Ownership: Private
Development stage: Other

Overview

River BioMedics has developed a proprietary human iPSC-derived, three-dimensional cardiac tissue model that enables direct functional assessment of novel drug targets and candidate compounds. Their approach combines GWAS-based target identification with human-relevant functional validation to improve translation into clinical efficacy. The company’s lead program has completed initial target validation and entered the hit-finding phase for small molecule development against heart failure. No clinical results have been reported yet; all programs are preclinical or earlier.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on River BioMedics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on River BioMedics.

Explore the full profile